Effect of ipratropium on nasal reactivity to histamine and eosinophil influx in perennial allergic rhinitis

P. Górski, K. Pazdrak, U. Ruta

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In a double-blind, placebo-controlled study nasal saline and histamine provocation tests were performed in patients with perennial allergic rhinitis in order to assess changes in eosinophil influx and non-specific nasal reactivity after 8 days of treatment with ipratropium bromide. A "nasal pool" method was used to trace changes in protein level and eosinophil influx into nasal secretions. Treatment with ipratropium 80 mg q.i.d. caused a significant decrease in the albumin and total protein level in saline washings and induced a five-fold increase in eosinophils as compared to the placebo treatment. The nasal mucosal response to histamine, assessed as the number of sneezes and protein level, was more responsive to ipratropium treatment than the mucosa from placebo-treated subjects. Since eosinophil numbers were correlated with an increase in the vascular and sneezing responses, it appears that ipratropium potentiates inflammatory mechanisms when used in subjects with an allergy in the nasal mucosa.

Original languageEnglish (US)
Pages (from-to)545-547
Number of pages3
JournalEuropean Journal of Clinical Pharmacology
Volume44
Issue number6
DOIs
StatePublished - Jul 1993
Externally publishedYes

Fingerprint

Rhinitis, Allergic, Perennial
Ipratropium
Nose
Eosinophils
Histamine
Placebos
Sneezing
Proteins
Nasal Mucosa
Therapeutics
Blood Vessels
Albumins
Hypersensitivity
Mucous Membrane

Keywords

  • Allergic rhinitis
  • Ipratropium
  • nasal reactivity

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)
  • Pharmacology

Cite this

Effect of ipratropium on nasal reactivity to histamine and eosinophil influx in perennial allergic rhinitis. / Górski, P.; Pazdrak, K.; Ruta, U.

In: European Journal of Clinical Pharmacology, Vol. 44, No. 6, 07.1993, p. 545-547.

Research output: Contribution to journalArticle

@article{b5042a9cc7b74812b323ac3ef15ed5b9,
title = "Effect of ipratropium on nasal reactivity to histamine and eosinophil influx in perennial allergic rhinitis",
abstract = "In a double-blind, placebo-controlled study nasal saline and histamine provocation tests were performed in patients with perennial allergic rhinitis in order to assess changes in eosinophil influx and non-specific nasal reactivity after 8 days of treatment with ipratropium bromide. A {"}nasal pool{"} method was used to trace changes in protein level and eosinophil influx into nasal secretions. Treatment with ipratropium 80 mg q.i.d. caused a significant decrease in the albumin and total protein level in saline washings and induced a five-fold increase in eosinophils as compared to the placebo treatment. The nasal mucosal response to histamine, assessed as the number of sneezes and protein level, was more responsive to ipratropium treatment than the mucosa from placebo-treated subjects. Since eosinophil numbers were correlated with an increase in the vascular and sneezing responses, it appears that ipratropium potentiates inflammatory mechanisms when used in subjects with an allergy in the nasal mucosa.",
keywords = "Allergic rhinitis, Ipratropium, nasal reactivity",
author = "P. G{\'o}rski and K. Pazdrak and U. Ruta",
year = "1993",
month = "7",
doi = "10.1007/BF02440856",
language = "English (US)",
volume = "44",
pages = "545--547",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Effect of ipratropium on nasal reactivity to histamine and eosinophil influx in perennial allergic rhinitis

AU - Górski, P.

AU - Pazdrak, K.

AU - Ruta, U.

PY - 1993/7

Y1 - 1993/7

N2 - In a double-blind, placebo-controlled study nasal saline and histamine provocation tests were performed in patients with perennial allergic rhinitis in order to assess changes in eosinophil influx and non-specific nasal reactivity after 8 days of treatment with ipratropium bromide. A "nasal pool" method was used to trace changes in protein level and eosinophil influx into nasal secretions. Treatment with ipratropium 80 mg q.i.d. caused a significant decrease in the albumin and total protein level in saline washings and induced a five-fold increase in eosinophils as compared to the placebo treatment. The nasal mucosal response to histamine, assessed as the number of sneezes and protein level, was more responsive to ipratropium treatment than the mucosa from placebo-treated subjects. Since eosinophil numbers were correlated with an increase in the vascular and sneezing responses, it appears that ipratropium potentiates inflammatory mechanisms when used in subjects with an allergy in the nasal mucosa.

AB - In a double-blind, placebo-controlled study nasal saline and histamine provocation tests were performed in patients with perennial allergic rhinitis in order to assess changes in eosinophil influx and non-specific nasal reactivity after 8 days of treatment with ipratropium bromide. A "nasal pool" method was used to trace changes in protein level and eosinophil influx into nasal secretions. Treatment with ipratropium 80 mg q.i.d. caused a significant decrease in the albumin and total protein level in saline washings and induced a five-fold increase in eosinophils as compared to the placebo treatment. The nasal mucosal response to histamine, assessed as the number of sneezes and protein level, was more responsive to ipratropium treatment than the mucosa from placebo-treated subjects. Since eosinophil numbers were correlated with an increase in the vascular and sneezing responses, it appears that ipratropium potentiates inflammatory mechanisms when used in subjects with an allergy in the nasal mucosa.

KW - Allergic rhinitis

KW - Ipratropium

KW - nasal reactivity

UR - http://www.scopus.com/inward/record.url?scp=0027280290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027280290&partnerID=8YFLogxK

U2 - 10.1007/BF02440856

DO - 10.1007/BF02440856

M3 - Article

C2 - 8405010

AN - SCOPUS:0027280290

VL - 44

SP - 545

EP - 547

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 6

ER -